Eli Lilly & Co.’s obesity drug tirzepatide helped patients on the highest tested dose shed about 21% of their body weight, or roughly 50 pounds, in a late-stage clinical trial.
Results ranged from an average loss of about 15% of body weight, or 35 pounds, on a low dose of the drug, to 21%, or 50 pounds, on the highest dose, Lilly said Thursday. Wegovy, a similar drug from Novo Nordisk A/S that tirzepatide would compete with if approved, yields average weight loss of about 15%.
